Hypertonic Saline Use in Preeclampsia
Preeclampsia
About this trial
This is an interventional treatment trial for Preeclampsia focused on measuring preeclampsia, hypertonic saline, diuresis
Eligibility Criteria
Inclusion Criteria: Women must have satisfied conditions for the diagnosis of preeclampsia (BP > 140/90, proteinuria ≥ 2+ or 300 mg in 24 hours) Women must have creatinine level below 1.6 mg/dL Women must have delivered their infant(s) prior to initiating therapy Women must be English-speaking Women must be medically stable at the time of entry into the study Women must be over the legal consenting age of 18 years Women must be consented prior to the administration of narcotics or other medications that may interfere with ability to give informed consent If not consented at the time of admission to Labor and Delivery, women must be comfortable enough with their contractions to complete the informed consent process without duress, or must be comfortable with regional anesthesia Women on magnesium sulfate will be eligible for entry after assessment of level of consciousness is deemed sufficient to give informed consent Exclusion Criteria: Women not able to understand the study because of language barriers or significant learning impairment Women less than 18 years of age Women who are medically unstable prior to recruitment or in whom expeditious delivery is warranted Women who have developed eclampsia (or seizures as a result of their preeclamptic condition) Women who have not consented prior to the administration of narcotics or other medications that may interfere with their ability to give informed consent Women whose pain severity in labor is such that they cannot participate in informed consent Women with a pre-existing cardiomyopathy Women with a sodium level < 130, or > 150 mEq/L Women with a creatinine level greater than 1.6 mg/dL Women with co-morbid conditions that affect renal function i.e. lupus nephritis, diabetic nephropathy, or pre-existing hypertensive kidney disease Women whose level of consciousness on magnesium sulfate is deemed insufficient to give informed consent
Sites / Locations
- Johns Hopkins University Hospital
- Johns Hopkins Bayview Medical Center